2022 Pediatric Grand Rounds | Optimizing Outcome for Patients with Mismatched Unrelated Donors (MMUD) HCT for Malignant Hematological Disease

Duarte, CA US
January 27, 2022

Hematopoietic stem cell transplants (HSCT) are standard of care for many patients with cancer, including subsets of patients with leukemia, myelodysplastic syndrome, lymphoma, benign hematological conditions, some genetic conditions, and some solid tumors.  A barrier to offering transplant has been identifying a suitable donor, however, advances in graft versus host disease (GvHD) mitigation strategies have allowed for more aggressive donor-recipient matches.  

The purpose of this lecture is to update pediatric oncologists on outcome data in utilizing post-transplant cyclophosphamide in GvHD mitigation and the impact on mismatched unrelated donor transplants.
 

Target Audience

City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.

Learning Objectives

  • Identify patients and disease subsets eligible for mismatched unrelated donors (MMUD) with post-transplant cyclophosphamide.
  • Examine outcomes of patients who undergo MMUD with post-transplant cyclophosphamide.
  • Integrate strategies to mitigate graft versus host disease (GvHD) in MMUD hematopoietic stem cell transplant (HSCT).
  • Identify possible avenues to collaborate on future trials that encompass the adolescent and young adult (AYA) population.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2022 Pediatric Grand Rounds | Optimizing Outcome for Patients with Mismatched Unrelated Donors (MMUD) HCT for Malignant Hematological Disease for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
01/27/2022
Activity expires: 
02/01/2022
Event starts: 
01/27/2022 - 12:00pm PST
Event ends: 
01/27/2022 - 1:00pm PST
Add to calendar: 
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Monzr M. Al Malki, MD   Director, Unrelated Donor Program & Haploidentical Transplant Program; Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation; City of Hope

Dr. Al Malki has indicated he has nothing to disclose. 

Dr. Al Malki will be discussing the off-label or investigational use of Cyclophosphamide. 

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2022 Pediatric Grand Rounds | Optimizing Outcome for Patients with Mismatched Unrelated Donors (MMUD) HCT for Malignant Hematological Disease for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.